Merus N.V. (MRUS)
NASDAQ: MRUS · Real-Time Price · USD
56.21
+0.20 (0.36%)
Jun 6, 2025, 4:00 PM - Market closed
Merus Revenue
Merus had revenue of $26.49M in the quarter ending March 31, 2025, with 235.76% growth. This brings the company's revenue in the last twelve months to $54.73M, up 42.77% year-over-year. In the year 2024, Merus had annual revenue of $36.13M, down -17.78%.
Revenue (ttm)
$54.73M
Revenue Growth
+42.77%
P/S Ratio
68.76
Revenue / Employee
$170,505
Employees
321
Market Cap
4.19B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 36.13M | -7.81M | -17.78% |
Dec 31, 2023 | 43.95M | 2.36M | 5.68% |
Dec 31, 2022 | 41.59M | -7.52M | -15.32% |
Dec 31, 2021 | 49.11M | 19.16M | 64.00% |
Dec 31, 2020 | 29.94M | -1.19M | -3.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
MRUS News
- 5 days ago - Merus N.V. Announces Pricing of Public Offering of Common Shares - GlobeNewsWire
- 5 days ago - Merus N.V. Announces Proposed Public Offering of Common Shares - GlobeNewsWire
- 12 days ago - Merus to Present at Upcoming Investor Conferences - GlobeNewsWire
- 17 days ago - Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC - GlobeNewsWire
- 24 days ago - Merus Announces the Journal Publication of Petosemtamab Mechanism of Action - GlobeNewsWire
- 4 weeks ago - Merus to Present at BofA Securities 2025 Health Care Conference - GlobeNewsWire
- 4 weeks ago - Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting - GlobeNewsWire